Evidence map›Paper›PMID 38560203›Full record

ArticleHeliyon2024

Lung adenocarcinoma patients with

Yanmei Peng, Vinicius Ernani, Dan Liu, Qian Guo, Markay Hopps, Joseph C Cappelleri, Ruchi Gupta, Mariza de Andrade, Jun Chen, Eunhee S Yi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Yanmei PengDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, 85259, USA.
Vinicius ErnaniDivision of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, AZ, 85054, USA.
Dan LiuDivision of Pulmonary & Critical Care Medicine, West China Hospital, Sichuan University, Chengdu, 610064, China.
Qian GuoDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, 610041, China.
Markay HoppsVaccine R&D, Pfizer Inc, New York, NY, 10017, USA.
Joseph C CappelleriExecutive Director of Biostatistics, Pfizer Inc, Groton, CT, 06340, USA.
Ruchi GuptaDivision of Biostatistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.
Mariza de AndradeDivision of Biostatistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 55905, USA.
Jun ChenThe Second Affiliated Hospital of Dalian Medical University, Shahekou District, Dalian, 116023, China.
Eunhee S YiDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, 55905, USA.
Ping YangDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, AZ, 85259, USA.
Mayo Clinic in Florida · USWinnMed · USMayo Clinic in Arizona · USPfizer (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients and methods: This patient cohort study included all never- (<100 cigarettes lifetime) and light- (100 cigarettes-20 pack-years) smokers, and a sample of heavy-smokers. Results: Of the 571 total patients, Conclusions: The

Indexed as

Lung adenocarcinomaROS1SexSmoking intensitySurvival

Identifiers

PMID38560203
PMCPMC10981064
OpenAlexW4392881931

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.